Biogen Idec to Present Hemophilia Data at ASH
December 3, 2014; Posted by: WeBleed staff
Biogen Idec to announce data findings on ELOCTATE and ALPROLIX at ASH meeting.
In an article posted Business Wire today, Biogen Idec announced they will present data on their hemophilia therapies at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California this weekend. Overall, the company will present 7 abstracts and two oral presentations about their role in the hematology world. Topics will include the following:
- Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia A (Kids-ALONG) – ELOCTATE
- Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes – ELOCTATE
- Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes – ALPROLIX
“We believe the growing body of data from clinical trials of ELOCTATE and ALPROLIX will further enhance physician understanding of the therapies’ clinical value,” said Aoife Brennan, M.D., vice president of Hematology Clinical Development at Biogen Idec. “This research underscores our commitment to advancing the treatment of hemophilia.”
The ASH Annual Meeting is always filled with new and exciting information and WeBleed will post updates as they become available.
Photo Credit – Biogen Idec
webleed.org – your source for bleeding news!
